Sequential chemotherapy-radiotherapy as adjuvant treatment of high-risk endometrial carcinoma: a retrospective review of the Manchester experience

Objective: The optimum sequencing of adjuvant treatment in patients with high-risk endometrial cancer remains contentious. Here, we report the outcomes of women treated in Manchester, United Kingdom, where sequential chemotherapy-radiotherapy is the standard adjuvant treatment approach for these patients. Methods: A retrospective analysis was carried out on 106 consecutive patients referred for adjuvant treatment of high-risk endometrial cancer in 2014 and 2015. High-risk endometrial cancer was defined as: International Federation of Gynaecology and Obstetrics (2009) stage I grade 3 endometrioid carcinoma with deep myometrial invasion and/or lymphovascular space invasion, stage II–III endometrioid carcinoma, or any other histological subtype with stage I–III disease. Adjuvant treatment included carboplatin (AUC5) and paclitaxel (175 mg/m2) every 21 days for 4/6 cycles, followed by external beam pelvic radiotherapy (40 Gy in 20 fractions#) or vaginal brachytherapy (28 Gy in 2 fractions#) or both. Primary outcome measures were recurrence free survival (RFS), overall survival (OS) and treatment-related toxicity. Results: Seventy-nine percent of patients were treated with sequential chemotherapy-radiotherapy. After a median follow-up of 64.4 months, 5-year RFS was 70% (95% CI 60.8–80.6%) and 5-year OS was 71.4% (95% CI 62.3–81.7%). Single modality adjuvant therapy was given for patient choice or contra-indications to treatment. Patients tolerated sequential treatment well; 96% of patients completed all treatment and 20% of patients had ≥$\ge$grade 3 adverse events. Conclusions: Sequential chemotherapy-radiotherapy as adjuvant treatment for high-risk endometrial cancer was tolerable and was associated with survival outcomes consistent with recent international phase III clinical trials.

Endometrial cancer; Chemotherapy; Radiotherapy; Brachytherapy

[1] Cancer Research UK. Uterine Cancer Statistics. 2020. Available at: https://www.cancerresearchuk.org/health-professional/canc er-statistics/statistics-by-cancer-type/uterine-cancer#heading-Zero (Accessed: 15 April 2020).

[2] Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. International Journal of Gynecologic Cancer. 2016; 27: 16–41.

[3] Network NCC. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Journal of the National Comprehensive Cancer Network. 2020.

[4] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multi-centre, randomised, phase 3 trial. Lancet Oncology. 2018; 19: 295–309.

[5] Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. British Journal of Cancer. 2006; 95: 266–271.

[6] Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecologic Oncology. 2009; 112: 543–552.

[7] Hogberg T, Signorelli M, de Oliveira CF, Fossati R, Lissoni AA, Sorbe B, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. European Journal of Cancer. 2010; 46: 2422–2431.

[8] Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. Journal of Clinical Oncology. 2019; 37: 1810–1808.

[9] de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology. 2019; 20: 1273–1285.

[10] Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine. 2019; 380: 2317–2326.

[11] Ko EM, Brensinger CM, Cory L, Giuntoli RL, Haggerty AF, Latif NA, et al. Utilization and survival outcomes of sequential, concurrent and sandwich therapies for advanced stage endometrial ca-cers by histology. Gynecologic Oncology. 2020; 159: 394–401.

[12] Creasman W. Revised FIGO staging for carcinoma of the endometrium. International Journal of Gynaecology and Obstetrics. 2009; 105: 109.

[13] U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2010. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_ 4.03_2010-06-14_QuickReference_8.5x11.pdf (Accessed: 2 May 2020).

[14] León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adjuvant Therapy. Journal of Clinical Oncology. 2020; 38: 3388–3397.